rss
J Neurol Neurosurg Psychiatry 2007;78:944-948 doi:10.1136/jnnp.2006.097154
  • Paper

Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson’s disease

  1. A J Lees1,
  2. V Ratziu2,
  3. E Tolosa3,
  4. W H Oertel4
  1. 1Reta Lila Weston Institute of Neurological Studies, University College London, London, UK
  2. 2Hôpital Pitié-Salpêtrière, Université Pierre et Marie Curie, Paris, France
  3. 3Servicio Neurologia, Hospital Clinic Universitat de Barcelona, IDIBAPS, Barcelona, Spain
  4. 4Philipps-Universitat, Marburg, Germany
  1. Correspondence to:
 Dr A J Lees
 Reta Lila Weston Institute for Neurological Studies, University College London, 1 Wakefield St, London WC1N 1PJ, UK;alees{at}ion.ucl.ac.uk
  • Received 5 May 2006
  • Accepted 18 October 2006
  • Revised 20 September 2006
  • Published Online First 10 November 2006

Abstract

Objective: The safety and tolerability of adjunctive tolcapone initiated simultaneously with levodopa was evaluated with a focus on increases in liver transaminase and hepatotoxicity.

Methods: 677 levodopa-naïve patients with early stage Parkinson’s disease (PD) were randomised to receive placebo or tolcapone 100 mg three times daily, added to standard doses of levodopa plus carbidopa or benserazide.

Results: Increases in liver transaminase above the upper limit of normal (ULN) occurred in 69/342 (20.2%) and 92/335 (27.5%) patients in the placebo and tolcapone groups, respectively. Increases ≥3 times the ULN occurred in 4/342 (1.2%) and 6/335 (1.8%) patients receiving placebo and tolcapone, respectively (p = 0.5). Liver transaminase values returned to normal in 65% of placebo and 80% of tolcapone treated patients. No instances of serious hepatotoxicity were seen. Diarrhoea was the most commonly reported AE—36/342 (11.0%) placebo v 98/335 (29.0%) tolcapone—and caused discontinuation in 9.9% of tolcapone treated patients. Overall, study discontinuation due to adverse effects was 2.9% in the placebo group and 17.3% in the tolcapone group.

Conclusions: Tolcapone seemed to be safe and was generally well tolerated as an adjunctive treatment in patients starting treatment with carbidopa/levodopa for symptomatic PD. Mild increases in transaminase levels—<3 times the ULN—occurred commonly in both placebo and tolcapone treated patients, whereas potentially serious increases of up to ≥3 times the ULN were infrequent.

Footnotes

  • Published Online First 20 November 2006

  • Competing interests: None declared.

This Article

  1. Abstract
  2. Full text
  3. PDF
  4. All versions of this article:
    1. jnnp.2006.097154v1
    2. jnnp.2006.097154v2
    3. 78/9/944 most recent

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

BMJ Careers - Latest neurology and neurosurgery jobs